Caitlin Eicher

Learn More
BACKGROUND Growth of selected castration-resistant prostate cancer (CRPC) cell lines and animal models can be repressed by reexposure to androgens. Low doses of androgens, however, can stimulate tumor growth. OBJECTIVE We performed a phase 1 clinical trial to determine the safety of high-dose exogenous testosterone in patients with castration-resistant(More)
PURPOSE We defined the antitumor effects of bortezomib alone and in combination with prednisone in patients with progressive, castration resistant metastatic prostate cancer. MATERIALS AND METHODS A total of 30 men with progressive castration resistant disease were treated in 2 groups. Cohort 1 received 1.5 mg/m2 bortezomib intravenously twice weekly for(More)
PURPOSE To investigate the safety and feasibility of rapid androgen cycling for men with progressive prostate cancer. EXPERIMENTAL DESIGN Schedule 1 included a 4-week induction of androgen depletion, followed by 4-week treatment cycles of a monthly gonadotropin-releasing hormone agonist, testosterone on days 1 to 7, and an estrogen patch on days 8 to 21.(More)
14520 Background: Inactivation of the Pten tumor suppressor gene, leading to constitutive activation of the PI3K/AKT/mTOR pathway, is correlated with resistance to EGFR-targeted therapies. This trial tested the concept that inhibition of mTOR by RAD 001 (NOVARTIS) will restore sensitivity to EGFR inhibition by gefitinib (ASTRA ZENECA), in patients with(More)
INTRODUCTION Research examining the relationship between social capital and health in Latin America has been limited. The aim of this study is to evaluate the association between social capital and tobacco use in four low-income neighborhoods in Santiago, Chile. METHODS A multistage probability sample was used to select households in 4 of the 10 poorest(More)
4560 Background: Standard treatment for metastatic PC is androgen withdrawal. In preclinical studies, growth of selected PC cell lines and xenografts following prolonged androgen deprivation can be repressed with the re-introduction of high-dose androgens. We conducted a phase I trial to test the feasibility of this strategy in humans. METHODS Eligible(More)
  • 1